Femasys Inc
FEMY
查看详细走势图
0.861USD
+0.064+7.97%
收盘 12/19, 16:00（美东）报价延迟15分钟
40.73M总市值
亏损市盈率 TTM
盘中分时
1分
30分
1小时
日k
周k
月k
日k
今天
+7.97%
5天
+0.51%
1月
+7.60%
6月
+1.31%
今年开始到现在
-21.72%
1年
-21.00%
查看详细走势图
TradingKey Femasys Inc股票评分
单位: USD 更新时间: 2025-12-19操作建议
Femasys Inc当前公司基本面数据相对健康，增长潜力较大。当前估值合理，在医疗设备与耗材行业排名132/208位。机构持股占比非常高，近一月多位分析师给出公司评级为买入。最高目标价5.17。中期看，股价处于上升通道。近一个月，市场表现较差，但技术面评分较高。目前股价在压力位和支撑位之间，可以做区间波段操作。
Femasys Inc评分
压力支撑
由于公司未披露，未能获取相关数据
多维评测
本期评分
上期评分
分析师目标
根据
3
位分析师
买入
评级
5.167
目标均价
+532.01%
涨幅空间
数据免责声明：分析师评级与目标价由LSEG提供，仅供参考，不应当作投资建议
Femasys Inc亮点
亮点风险
Femasys Inc. is a biomedical company. The Company is focused on addressing the unmet needs of women worldwide with a broad portfolio of in-office, accessible, and therapeutic and diagnostic solutions. The Company has two lead product candidates: FemBloc and FemaSeed. FemBloc is a permanent birth control solution in development. Its permanent birth control solution in development includes its FemBloc system, which features dual intrauterine directional delivery targeting both fallopian tubes with a degradable blended biopolymer. FemaSeed is an artificial insemination infertility treatment. Its artificial insemination solution in development includes its FemaSeed product candidate for artificial insemination, which features single intrauterine directional delivery. It also developed FemCerv, which is an endocervical tissue sampler for cervical cancer diagnosis; FemVue, which is a companion diagnostic for fallopian tube assessment; FemCath, which is an intrauterine catheter, and FemChec.
业绩高增长
公司营业收入稳步增长，连续3年增长35.06%
业绩增长期
公司处于发展阶段，最新年度总收入1.63M美元
利润高增长
公司净利润处于行业前列，最新年度总收入1.63M美元
估值合理
公司最新PE估值-1.25，处于3年历史合理位
先锋集团持仓
明星投资者先锋集团持仓，最新持仓市值951.87K
活跃度增加
近期活跃度增加，过去20天平均换手率0.15
Femasys Inc新闻
即将为您带来更多新闻，敬请期待。。。
财务指标
每股收益
由于公司未披露，未能获取相关数据
营业总收入
由于公司未披露，未能获取相关数据
Femasys Inc简介
Femasys Inc. is a biomedical company. The Company is focused on addressing the unmet needs of women worldwide with a broad portfolio of in-office, accessible, and therapeutic and diagnostic solutions. The Company has two lead product candidates: FemBloc and FemaSeed. FemBloc is a permanent birth control solution in development. Its permanent birth control solution in development includes its FemBloc system, which features dual intrauterine directional delivery targeting both fallopian tubes with a degradable blended biopolymer. FemaSeed is an artificial insemination infertility treatment. Its artificial insemination solution in development includes its FemaSeed product candidate for artificial insemination, which features single intrauterine directional delivery. It also developed FemCerv, which is an endocervical tissue sampler for cervical cancer diagnosis; FemVue, which is a companion diagnostic for fallopian tube assessment; FemCath, which is an intrauterine catheter, and FemChec.
公司代码FEMY
公司Femasys Inc
CEOLee-Sepsick (Kathy)
网址https://www.femasys.com/
常见问题
Femasys Inc(FEMY)的当前股价是多少？
Femasys Inc(FEMY)的当前股价是 0.861。
Femasys Inc的股票代码是什么？
Femasys Inc的股票代码是FEMY。
Femasys Inc股票的52周最高点是多少？
Femasys Inc股票的52周最高点是1.800。
Femasys Inc股票的52周最低点是多少？
Femasys Inc股票的52周最低点是0.307。
Femasys Inc的市值是多少？
Femasys Inc的市值是40.73M。
Femasys Inc的净利润是多少？
Femasys Inc的净利润为-18.82M。
现在Femasys Inc(FEMY)的股票是买入、持有还是卖出？
根据分析师评级，Femasys Inc(FEMY)的总体评级为买入，目标价格为5.167。
Femasys Inc(FEMY)股票的每股收益（EPS TTM）是多少
Femasys Inc(FEMY)股票的每股收益（EPS TTM）是-0.687。
相关品种
-0.24%
+0.25%
+0.87%
+1.88%
+0.22%
-0.55%
+0.53%
+0.12%
+1.35%
-0.10%
-1.23%
-0.77%
+0.10%
+0.46%
+0.46%
+0.97%
+0.59%
+0.23%
+0.45%
+1.74%
